Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Osprey Pharmaceuticals USA
About
Osprey Pharmaceuticals USA develops novel protein therapeutics for the treatment of inflammatory and immune diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $11M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 3, 2008 | Series A | $11M | 1 | — | — | Detail |
| Jan 30, 2007 | Series Unknown | $9M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Novo Nordisk
|
— | Series A |
Reference Capital
|
— | Series Unknown |
